Advertisement Fidelity
Home > Boards > US OTC > Medical - Drugs >

Provectus Pharmaceuticals (PVCT)

Add PVCT Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Gulfbreeze, smitter, noretreat, buccaneer1961, TOB
Search This Board:
Last Post: 4/19/2014 12:39:53 PM - Followers: 122 - Board type: Free - Posts Today: 2

This board acts as a portal for PVCT investors, and retains the right to refuse service to individuals not in compliance with reasonable, responsible, and intelligible posting practices.

PVCT on YouTube...

Letter from the CEO Craig Dee's

We are a group of dedicated and entrepreneurial scientists, working together for the past 10 years, engaged in developing breakthrough technologies for cancer and other serious diseases. Our primary goal at Provectus is to develop alternative treatments that are safer, more effective, less invasive and more economical than conventional therapies.

Our Provectus Pharmatech division develops ethical pharmaceuticals for oncology and dermatology. Looking first to oncology, our novel drugs are designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing systemic side effects. In particular, our focus is on melanoma, breast and liver cancers – among the most difficult cancers to treat using conventional methods. We are very excited about the Phase I clinical trials of Provecta™ that began in 2005 for melanoma and breast cancer, and we are expanding to include liver cancer patients soon.

Targeting abnormal or diseased cells is also the approach we use in designing proprietary treatments for dermatological diseases, in particular, chronic, severe cases of psoriasis, eczema and acne. We anticipate that Phase II clinical trials of our topical agent Xantryl™ for psoriasis and eczema will begin soon. In addition, certain skin cancers may be targeted and treated more safely and effectively using Xantryl™.

In addition to our core pharmaceutical work, Provectus has developed a number of intellectual properties and technologies in the areas of medical devices and biotechnologies. Rather than dilute the efforts of Pharmatech, we are actively pursuing licensure, co-development, spin-offs and joint ventures of these technologies via our divisions Provectus Devicetech and Provectus Biotech. Devicetech encompasses both cosmetic and therapeutic treatments, with key attention to developing laser-based products to treat melanoma. Biotech is concentrating on producing vaccines to prevent certain cancers and other serious diseases, as well as detecting new viruses that could be associated with the onset of such diseases.

Our fourth division, Pure-ific Corp., is prepped to be sold or spun off to further develop its over-the-counter products. We are introducing professional skincare products for disposable glove users, and novel retail products for personal hygiene. In addition, we will be introducing an OTC product for acne sufferers.

We are proud of our intellectual capital at Provectus. We hold 15 U.S. patents in the pharmaceutical, medical device and biotech fields, with 19 additional patent applications in the works.

Provectus is a significant, emerging player in the huge and growing pharmaceutical industry. We believe in our potential to improve health care worldwide, using breakthrough products that are easy to manufacture and license, and economical to use. We appreciate your interest in our company, and welcome your comments and questions.

Craig Dees, Ph.D., CEO
Provectus Pharmaceuticals

PVCT 6 months chart:

Technical analysis:

PVCT News:



PVCT insiders transactions:


Drug Delivery Technology magazine special feature article "Revisiting Intralesional Delivery of Cancer Treatment", by Provectus CEO Craig Dees, Ph.D., compares Provectus’ novel cancer drugs to current cancer treatments.

May 17, 2007
Professor Peter Hersey, M.D. comments on PV-10 and a patient's response
Professor Peter Hersey, M.D., a professor of oncology at the University of Newcastle and Medical and Research Director of the Newcastle Melanoma Unit, comments on PV-10 and a patient's response.

Video can be viewed here.

This 15-minute clip follows the progress of an 86-year-old man treated with the drug. Prior to his treatment, his melanoma was so unresponsive to the current standard of care, including numerous invasive operations and toxic chemotherapy, that he was given only months to live.

Video can be viewed here.
Contact Info

Telephone: +1 (865) 769-4011
Fax: +1 (865) 769-4013

Mailing Address:
Provectus Pharmaceuticals, Inc.
7327 Oak Ridge Hwy
Knoxville, TN 37931 USA

Transfer Agent:
(i.e. stockholder records, transfer, change of address, etc.)
Atlas Stock Transfer
5899 South State Street, Suite # 24
Murray, UT 84107
Telephone: +1 (801) 266-7151
Fax: +1 (801) 262-0907

Investor Relations:
Joseph Kessler
The Investor Relations Group
11 Stone St., 3rd fl
New York, NY 10004
Telephone: 212-825-3210
Fax: 212-825-3229

Public Relations:
The Investor Relations Group
Janet Vasquez
Telephone: 212-825-3210

Investment Advisor:
Damon Testaverde
Network 1 Financial Securities
Telephone: +1 (800) 205-8031
Share Statistics
45.45 m
35.35 m

Non-Corp. Insider Hold'gs:
22.20% (as of 4/1/07)

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
PVCT News: Provectus Pharmaceuticals, Inc. Melanoma Version of PV-10 Completes Phase 2 and is Prepping for BTD 03/13/2014 12:04:00 PM
PVCT News: Provectus Pharmaceuticals, Inc. Melanoma Version of PV-10 Completes Phase 2 and is Prepping for BTD 02/27/2014 09:23:00 AM
PVCT News: Provectus Pharmaceuticals, Inc. Melanoma Version of PV-10 Completes Phase 2 and is Prepping for BTD 02/27/2014 07:00:00 AM
PVCT News: Provectus Pharmaceuticals, Inc. Analyst Research Report 01/22/2014 07:00:00 AM
News News Alert: Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) 04/18/2014 05:03:10 PM
#2192  Sticky Note PVCT 8k and Letter Exhibit attached for the smitter 01/24/14 06:37:45 AM
#610  Sticky Note Provectus Type C Meeting With FDA Oncology Division [SMART MONEY] 12/18/13 07:17:38 AM
#3503   What interest does it serve to stockholders to Groscoe 04/19/14 12:39:52 PM
#3502 found this^^ buccaneer1961 04/19/14 11:56:51 AM
#3501   The study shows...the bystander response observed in patients...[is] buccaneer1961 04/18/14 11:29:02 PM
#3500   new filing today buccaneer1961 04/18/14 05:07:09 PM
#3499   UNITED STATES buccaneer1961 04/18/14 05:06:26 PM
#3498   News buccaneer1961 04/18/14 11:12:13 AM
#3497   Per the Form D, Rule 506b exemption applies. Fruno 04/17/14 10:11:54 PM
#3496   Yes, but it's also only allowed to accredited laxerpro22 04/17/14 06:19:32 PM
#3495   Isn't a Form D for sale of securities? snidely 04/17/14 06:01:23 PM
#3494   Form D Filed vorlon1966 04/17/14 05:34:50 PM
#3493   New Moffitt article ( Fruno 04/17/14 03:52:02 PM
#3492   Thanks Tom SJI88 04/17/14 09:10:48 AM
#3491   SJ188 ,It could fall below 2 dollars, but 123tom 04/17/14 05:38:27 AM
#3490   Yes. Within 2 weeks is my time table. suberizedwrx 04/16/14 08:27:41 PM
#3489   Looks like the Biotechs are bouncing back looks Paulness 04/16/14 06:40:41 PM
#3488   Anyone see us under $2? Been on a SJI88 04/16/14 05:30:10 PM
#3487   I like that kind of idea. 123tom 04/16/14 02:32:56 PM
#3486   Debating Systemic Intralesional Therapies (April 16, 2014) buccaneer1961 04/16/14 11:23:39 AM
#3484   I have an idea for a small research thefamilyman 04/16/14 12:58:12 AM
#3483   Found this video by Dr. Andtbacka from the Fruno 04/15/14 10:21:14 PM
#3481   PVCT is well within the big 123tom 04/15/14 05:12:39 PM
#3480   "Rumor has indicated that it might have been laxerpro22 04/15/14 02:36:08 PM
#3479   Cantor walked away from the bid today vorlon1966 04/15/14 01:55:03 PM
#3477 New Post U laxerpro22 04/15/14 11:17:09 AM
#3476   We have dropped almost .70 in less than SJI88 04/15/14 11:13:43 AM
#3475   Yes. vorlon1966 04/15/14 11:12:27 AM
#3474   Anyone Have an L2 handy for PVCT? laxerpro22 04/15/14 10:44:02 AM
#3473   Why does Cantor F keep coming up around Gulfbreeze 04/15/14 10:08:04 AM
#3472   Sorry about the link. I was going Fruno 04/15/14 09:28:48 AM
#3471   You do know that this link you posted Paulness 04/14/14 11:10:23 PM
#3470   Video of Dr. Andtbacka's presentation at Hemonc. Fruno 04/14/14 08:55:08 PM
#3469   excellent comment ,Laxerpro. totally agree. 123tom 04/14/14 04:20:05 PM
#3468   My point is that many people here look tim779 04/14/14 03:36:56 PM
#3467   We're only 3 weeks in of a possible laxerpro22 04/14/14 03:24:06 PM
#3466   Thank you so much for clarifying Tim, very helpful. SJI88 04/14/14 03:17:38 PM
#3465   Why are so many people selling then? EODparty7 04/14/14 03:12:39 PM
#3464   They are called sellers. tim779 04/14/14 03:08:50 PM
#3463   Why so many shorts on good news? SJI88 04/14/14 02:21:23 PM
#3462   China news! This is great!! we are well EODparty7 04/14/14 09:40:17 AM
#3461   Big things happening, pvct seems to be on laxerpro22 04/14/14 07:50:42 AM
#3460   News headline Provectus Biopharmaceuticals Signs Agreement with China's Tririv GearUp 04/14/14 06:49:36 AM
#3459   COMMENTS ON the HemOnc Today Melanoma treatment debate. buccaneer1961 04/14/14 01:51:38 AM
#3457   that's more like it buccaneer1961 04/13/14 08:59:08 PM
#3456   I have been following this stock, since 2009, yaboy520 04/12/14 01:41:33 PM
#3455   I appreciate your level headed input. We'll suberizedwrx 04/11/14 02:57:40 PM
#3454   Thanks for your comments Suberizdwrx, 123tom 04/11/14 01:56:11 PM
#3453   Never know....NY is a dirty game. vorlon1966 04/11/14 01:15:00 PM
#3452   ...meaning they can be facilitating the shorts through Pvctguy 04/11/14 12:27:16 PM
#3451   i keep hitting my stink bids. lol. i PVCTorBust 04/11/14 12:26:37 PM
#3450   Yup. They cannot make markets but they can vorlon1966 04/11/14 12:20:56 PM